

Wietse Mulder steps down as CEO of GenDx, Maarten Penning appointed as General Manager

Utrecht, 29 June 2023,

The board of GenDx announces that Wietse Mulder PhD will step down as CEO per 1st of July. Per the same date, Maarten Penning PhD will assume the helm of the company and is appointed as General Manager of the company and also executive director of the GenDx Board, joining non-executive directors, Denis Fortier and Hervé Duchesne de Lamotte.

The Board happily announces that Mulder will continue to support GenDx as Ambassador for an undefined period of time. In his Ambassador role he will support GenDx Leadership Team (members) but will devote his attention mostly to marketing and communication, including GenDx's corporate social responsibility activities. He will also continue to actively represent GenDx, locally, but also at international conferences.

Since January 2004, Mulder has devoted full attention to the GenDx project. From writing a draft business plan, establishing the company in 2005, developing new products, till today where GenDx is on the doorstep entering the field of companion diagnostics and cfDNA diagnostics.

It is impossible to fully express what Mulder does mean for GenDx and colleagues. It is clear that without him, GenDx would not be the well-respected company in the field of transplant diagnostics that currently it is. We are grateful for the meaningful impact he has accomplished for GenDx, the colleagues, our partners and the transplant patients.

Wietse Mulder comments: "I realize that leaving executive office of GenDx is a next step in my career as Life Science entrepreneur. I am proud that together with Erik Rozemuller and all GenDx colleagues, we have achieved so many meaningful products and services. I enjoyed having worked for almost 20 years at GenDx in a truly collaborative atmosphere, I certainly will miss that. I am proud to see that we have maintained the same spirit since we started. Focused on educating workers in the transplant field, enabling better HLA typing, allowing better matching and together with accurate transplant monitoring, increasing the success of solid organ and stem cell transplantation."

Maarten Penning is trained as a molecular biologist and employed at GenDx for more than 13 years. He has executed various roles at the company ranging from project management, business development till his current job as CTO where he oversees the global R&D of Eurobio Scientific group. Penning also chaperoned as deputy CEO the GenDx leadership team for already several years. Penning is a trusted and respected person in the field. We are confident that with him at the helm of the executive office, the transition to a new era for GenDx, part of the Eurobio Scientific group, will be a smooth process.

Maarten Penning comments: "It is an honor to be the successor of Wietse Mulder, after working together since 2010. I am looking forward to continue to support and educate our partners in the transplant diagnostic field. I am motivated to make GenDx even more successful in the coming years, together with the GenDx Leadership Team and all other fantastic GenDx colleagues. Based

on the GenDx experiences, I am confident that together we will also have a meaningful contribution to the success of EuroBio Scientific Group. “

About GenDx, a Eurobio Scientific Company

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplantation and companion diagnostics. To support GenDx's USA customers it has an office near O'Hare airport, Chicago, IL. GenDx specializes in (Sanger and NGS) HLA sequencing-based typing strategies and offers both reagents and software. As one of the sequencing pioneering companies in the HLA field, GenDx started offering NGS strategies in 2013, consisting of NGSgo[®] reagents and the software package NGSengine[®] for various NGS platforms. Additionally, GenDx offers products for chimerism monitoring by qPCR and - launched recently - by NGS: NGStrack[®] & TRKengine[®]. Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx Education organizes dedicated HLA sequence-based typing and chimerism monitoring training courses worldwide on a regular basis for anyone working in tissue typing or research laboratories, blood banks, and donor registries. GenDx is based in the Alexander Numan building at the Utrecht Science Park, the Netherlands and was founded in 2005 by Erik Rozemuller PhD, Wietse Mulder PhD. In October 2022, Eurobio Scientific acquired all shares of GenDx. For further information about GenDx visit www.GenDx.com.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 180 employees and three production units based in France, in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands. Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM. For more information, please visit : www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

GenDx Yalelaan 48
3584 CM Utrecht
The Netherlands
Office: +31 30 252 3799
E-mail: info@gendx.com

Contact GenDx
Hanneke Merkens PhD
Director Marketing and Communication
Email: h.merkens@gendx.com
Phone: +31 6 12 65 5845